D-Ribose-L-cysteine

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H596067

CAS#: 232617-15-1

Description: D-Ribose-L-cysteine is a precursor to the antioxidant glutathione.

Chemical Structure

img
D-Ribose-L-cysteine
CAS# 232617-15-1
Instruction

Theoretical Analysis

Hodoodo Cat#: H596067
Name: D-Ribose-L-cysteine
CAS#: 232617-15-1
Chemical Formula: C8H15NO6S
Exact Mass: 253.06
Molecular Weight: 253.260
Elemental Analysis: C, 37.94; H, 5.97; N, 5.53; O, 37.90; S, 12.66

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: D-Ribose-L-cysteine; Ribcys; J424.013H; Riboceine; D Ribose L cysteine; DRiboseLcysteine;

IUPAC/Chemical Name: (4R)-2-((1R,2R,3R)-1,2,3,4-tetrahydroxybutyl)thiazolidine-4-carboxylic acid

InChi Key: AGZXTDUDXXPCMJ-HZYAIORGSA-N

InChi Code: InChI=1S/C8H15NO6S/c10-1-4(11)5(12)6(13)7-9-3(2-16-7)8(14)15/h3-7,9-13H,1-2H2,(H,14,15)/t3-,4+,5+,6+,7?/m0/s1

SMILES Code: O=C([C@H]1NC([C@H](O)[C@H](O)[C@H](O)CO)SC1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 253.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Falana B, Adeleke O, Orenolu M, Osinubi A, Oyewopo A. Effect of D-ribose-L-cysteine on aluminum induced testicular damage in male Sprague-Dawley rats. JBRA Assist Reprod. 2017 Jun 1;21(2):94-100. doi: 10.5935/1518-0557.20170023. PubMed PMID: 28609275; PubMed Central PMCID: PMC5473701.

2: Saltman AE. D-ribose-L-cysteine supplementation enhances wound healing in a rodent model. Am J Surg. 2015 Jul;210(1):153-8. doi: 10.1016/j.amjsurg.2014.11.014. Epub 2015 Mar 27. PubMed PMID: 25935230.

3: Kader T, Porteous CM, Williams MJ, Gieseg SP, McCormick SP. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. Atherosclerosis. 2014 Dec;237(2):725-33. doi: 10.1016/j.atherosclerosis.2014.10.101. Epub 2014 Nov 1. PubMed PMID: 25463112.

4: Im GY, Kazi S, Thung SN, Perumalswami PV. A maxed-out liver: a case of acute-on-chronic liver failure. Semin Liver Dis. 2011 Nov;31(4):420-6. doi: 10.1055/s-0031-1297930. Epub 2011 Dec 21. PubMed PMID: 22189981.

5: Jurkowska H, Uchacz T, Roberts J, Wróbel M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation. Amino Acids. 2011 Jun;41(1):131-9. doi: 10.1007/s00726-010-0593-4. Epub 2010 Apr 23. PubMed PMID: 20414692.

6: Oz HS, Chen TS, Nagasawa H. Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Transl Res. 2007 Aug;150(2):122-9. Epub 2007 May 23. PubMed PMID: 17656332; PubMed Central PMCID: PMC1991291.

7: Slitt AM, Dominick PK, Roberts JC, Cohen SD. Effect of ribose cysteine pretreatment on hepatic and renal acetaminophen metabolite formation and glutathione depletion. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):487-94. PubMed PMID: 15910414.

8: Waldren CA, Vannais DB, Ueno AM. A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by ascorbate and RibCys but not DMSO. Mutat Res. 2004 Jul 13;551(1-2):255-65. PubMed PMID: 15225598.

9: Lenarczyk M, Ueno A, Vannais DB, Kraemer S, Kronenberg A, Roberts JC, Tatsumi K, Hei TK, Waldren CA. The "pro-drug" RibCys decreases the mutagenicity of high-LET radiation in cultured mammalian cells. Radiat Res. 2003 Nov;160(5):579-83. PubMed PMID: 14565824.

10: Ueno A, Vannais D, Lenarczyk M, Waldren CA. Ascorbate, added after irradiation, reduces the mutant yield and alters the spectrum of CD59- mutations in A(L) cells irradiated with high LET carbon ions. J Radiat Res. 2002 Dec;43 Suppl:S245-9. PubMed PMID: 12793767.

11: Rathbun WB, Killen CE, Holleschau AM, Nagasawa HT. Maintenance of hepatic glutathione homeostasis and prevention of acetaminophen-induced cataract in mice by L-cysteine prodrugs. Biochem Pharmacol. 1996 May 3;51(9):1111-6. PubMed PMID: 8645331.

12: Carroll MP, Zera RT, Roberts JC, Schlafmann SE, Feeney DA, Johnston GR, West MA, Bubrick MP. Efficacy of radioprotective agents in preventing small and large bowel radiation injury. Dis Colon Rectum. 1995 Jul;38(7):716-22. PubMed PMID: 7607031.

13: Roberts JC, Francetic DJ, Zera RT. Chemoprotection against cyclophosphamide-induced urotoxicity: comparison of nine thiol protective agents. Anticancer Res. 1994 Mar-Apr;14(2A):389-95. PubMed PMID: 8017838.

14: Roberts JC, Francetic DJ. Chemoprotection against cyclophosphamide-induced urotoxicity: ribose-cysteine. Anticancer Res. 1994 Mar-Apr;14(2A):383-7. PubMed PMID: 8017837.

15: Rowe JK, Zera RT, Madoff RD, Fink AS, Roberts JC, Johnston GR, Feeney DA, Young HL, Bubrick MP. Protective effect of RibCys following high-dose irradiation of the rectosigmoid. Dis Colon Rectum. 1993 Jul;36(7):681-8. PubMed PMID: 8348853.

16: Roberts JC, Charyulu RL, Zera RT, Nagasawa HT. Protection against acetaminophen hepatotoxicity by ribose-cysteine (RibCys). Pharmacol Toxicol. 1992 Apr;70(4):281-5. PubMed PMID: 1608914.

17: Shirota FN, Elberling JA, Nagasawa HT, DeMaster EG. Failure of glutathione and cysteine prodrugs to block the chlorpropamide-induced inhibition of aldehyde dehydrogenase in vivo. Biochem Pharmacol. 1992 Feb 18;43(4):916-8. PubMed PMID: 1540248.

18: Roberts JC, Francetic DJ. Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys. Toxicol Lett. 1991 Dec;59(1-3):245-51. PubMed PMID: 1755032.

19: Roberts JC, Francetic DJ, Zera RT. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemother Pharmacol. 1991;28(3):166-70. PubMed PMID: 1855273.